Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support
Launched by THE YOUNG INVESTIGATOR GROUP OF CARDIOVASCULAR RESEARCH · Oct 20, 2022
Trial Information
Current as of June 13, 2025
Unknown status
Keywords
ClinConnect Summary
Background and study rationale:
Ivabradine is a Heart Rate (HR) lowering agent which acts by inhibiting the If current in the sinoatrial node. It is currently indicated in patients with chronic heart failure with reduced ejection fraction (HFrEF). Dobutamine is an inotropic drug used in cardiogenic shock patients and it is associated with an increase in HR and incidence of cardiac arrhythmias.2 However, studies have suggested that increased heart rate may be deleterious in decompensated HFrEF due to an inverted Bowditch-Treppe response. Data regarding the safety and efficacy of ivabradine ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Decompensated heart failure with reduced ejection fraction (HFrEF) admitted for cardiogenic shock requiring inotropic support.
- Exclusion Criteria:
- • Decompensated heart failure with reduced ejection fraction (HFrEF) not requiring inotropic support.
- • Patients with no oral intake
- • Patients who refused to sign the consent
About The Young Investigator Group Of Cardiovascular Research
The Young Investigator Group of Cardiovascular Research is a dedicated sponsor focused on advancing the field of cardiovascular medicine through innovative research led by emerging scientists. Committed to fostering the next generation of researchers, the group emphasizes collaboration, mentorship, and the dissemination of novel findings that address critical challenges in cardiovascular health. By supporting clinical trials and research initiatives, the organization aims to enhance understanding of cardiovascular diseases, promote evidence-based practices, and ultimately improve patient outcomes. Through its initiatives, the Young Investigator Group strives to cultivate a vibrant community of young researchers who are poised to make significant contributions to the future of cardiovascular science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Alexandria, , Egypt
Alexandria, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials